- Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Im, S.A., Kim, S.B., Lee, M.H., Im, Y.H., Lee, K.H., Song, H.S., Lee, M.A., Lee, J., Lee, N.S., Ham, H.S., Kim, T.Y., Park, Y.H., Lee, K.E., Kim, K.W., Seo, J.H., Lee, S.N., Hong, Y.S., Bang, Y.J., Kim, W.K., Park, H.S. Oncol. Rep. (2005)